Liminatus Pharma Inc. (LIMN)
NasdaqCM: LIMN
· Real-Time Price · USD
0.11
+0.00 (0.00%)
At close: Aug 12, 2026, 3:57 PM
0.11
-1.38%
After-hours: 7:48 PM
Liminatus Pharma Inc. (LIMN) Stock Price, Analysis & Data
0.00% (1D)
| Bid | 0.1 |
| Market Cap | 7.29M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11M |
| Beta | 0.74 |
| EPS (ttm) | -0.24 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | -36.17 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 0.12 |
| Volume | 1,140,478 |
| Avg. Volume (20D) | 31,851,041 |
| Open | 0.11 |
| Previous Close | 0.11 |
| Day's Range | 0.11 - 0.11 |
| 52-Week Range | 0.10 - 4.85 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About LIMN
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California....
Industry Biotechnology
Sector Healthcare
IPO Date May 2, 2025
Employees 1
Stock Exchange NasdaqCM
Ticker Symbol LIMN
Website https://liminatuspharma.com
Financial Performance
In 2025, Liminatus Pharma's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -10.21M, an increase of 187.81%.
Financial Statements6 months ago · Associated Press Finance
BC-Most Active StocksPagaya Technologies Ltd. 23,855,890 15.29